Home | About IJMPO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Login 
Indian Journal of Medical and Paediatric Oncology
Search Article 
Advanced search 
Year : 2000  |  Volume : 21  |  Issue : 1  |  Page : 32-35

Drug review : topotecan.

Rajasthan Cancer Care Centre, Jaipur

Correspondence Address:
N Somani
Rajasthan Cancer Care Centre, Jaipur

Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

Topotecan is a semi synthetic topoisomerase -1 inhibitor. It acts by interfering with DNA repair and replication. It is mainly indicated for cancer of ovary, small cell cancer of lung (USA-FDA has approved it as the second line agent for this indication), myelodysplastic syndrome, refractory acute leukaemias, neuroblastoma, Ewing's sarcoma, retinoblastoma, hepatoblastoma, rhabdomyosarcoma, malignant glioma and other brain tumours. It is excreted by the kidneys and hence it needs dose modification for the impaired function. Neutropaenia is the dose limiting toxicity.

[PDF Not available]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal